Navigation Links
Tolerx Named as One of the 'Fierce 15' Biotech Companies of 2008
Date:6/24/2008

ceutical company engaged in the discovery and development of novel therapies for immune-mediated diseases. Tolerx currently has two antibodies in clinical development for the potential treatment of various autoimmune indications: otelixizumab, an anti-CD3 MAb which is being developed in collaboration with GlaxoSmithKline and a modified form of TRX1, which is being developed in collaboration with Genentech, Inc. Tolerx is also engaged in preclinical development of new product candidates that circumvent immune system tolerance. These product candidates are being evaluated for the treatment of cancer or chronic viral diseases. For more information, please visit http://www.tolerx.com.

Tolerx Forward-Looking Statements

This press release contains certain statements that include the word "potential". Such statements, which are not historical facts, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). Statements regarding outcomes sought to be realized in the clinical trials or preclinical development, and the potential for Tolerx to make a significant impact in the biotech market are all forward-looking statements. Such forward-looking statements involve risks, uncertainties and other factors that may cause the actual performance or achievements of Tolerx to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. There can be no certainty that Tolerx will advance any clinical candidate or other component of its pipeline to the clinic, to the next regulatory step or to commercialization or that Tolerx will ever realize revenue from commercialization of product candidates it is currently or may in the future seek to develop. Factors and risks that may impact management's expectations and affect the forward-looking statements include but are not be limit
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Brian Levy, OD, MSc, Named Chief Operating Officer of Danube Pharmaceuticals
2. Barrett Katz, MD, MBA, Named CEO of Danube Pharmaceuticals
3. Ten Latin American Scientists Named 2008 Pew Fellows in the Biomedical Sciences
4. Netsmarts Kevin Scalia Named Chair of the Software and Technology Vendors Association
5. GlaxoSmithKline Named A Top Employer for Promoting Healthy Lifestyles
6. Professors Marc Feldmann and Sir Ravinder Maini Named Winners of the 2008 Dr. Paul Janssen Award for Biomedical Research
7. President and CEO of Velcura Therapeutics Inc. Named the 2008 Grant Thornton Leader and Innovator of the Year
8. Black Box Network Services, ABTECH, Verizon Business and Wyle Named Top Siemens Reseller Partners
9. BioNanomatrix Named Best Management Team at the 2008 Ben Franklin Emerging Business Awards
10. Ash Stevens Inc. Named One of Michigan 50 Companies to Watch
11. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... July 22, 2014 Hussey Copper , ... 29 antimicrobial copper announces Pullman Regional Hospital,s conversion ... EPA-registered antimicrobial solid touch surface, at a nominal cost.  ... MRSA, E-coli and other bacteria within 2 hours of exposure ... against bacteria and infectious diseases in its facilities. ...
(Date:7/22/2014)... Mass. , July 22, 2014  The ... $650 million from philanthropist Ted Stanley ... and bringing new treatments based on molecular understanding ... world. The Stanley commitment – ... the largest for scientific research in general – ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Holomic ... with the debut of its fluorescent immunoassay reader, ... Chemistry (AACC) meeting in Chicago, July 28-31, 2014. ... top versions, the HRDR-300 is a highly sensitive, ... to analyze fluorescent lateral flow immunoassays with high ...
(Date:7/22/2014)... The next session of Clinovo’s ... will comprise of the increasingly popular ‘Base SAS’ and ... a series of technical hands-on classes for entry-level to ... the next step in their professional careers. , The ... Jennifer Kang, Senior Statistician at Genentech and former Senior ...
Breaking Biology Technology:Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 2$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 3$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 4$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 5$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 6$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 7$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 8$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 9$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 10Holomic to Debut HRDR-300 Fluorescent Immunoassay Reader at the AACC 2014 2Clinovo TechTrainings: Next Session of SAS and CDISC Classes Start 9th September, 2014 2Clinovo TechTrainings: Next Session of SAS and CDISC Classes Start 9th September, 2014 3
... of electrospinning for applications primarily within the medical device ... announces a new technology platform in the field of ... ranging from the nano to microscale. Zeus is able ... and bioabsorbables. The result is a broad range of ...
... Zeus is slated to manufacture parts and assemble MOD® units, an ... ... Orangeburg, SC (PRWEB) February 15, 2009 -- Zeus, Inc., a ... pleased to announce a new partnership with Avancen MOD Corporation. ...
... free webinars providing continuing education for Chemists and Chemical Engineers. Visit ... as a listing of over sixty On-Demand Webinars. For your convenience, the ... , ... Columbia, MD (PRWEB) February 14, 2009 -- Each free ...
Cached Biology Technology:Electrospinning: Emerging New Technology at Zeus 2Zeus Partners with Avancen MOD Corp. 2Free Webinars in Chemistry and Chemical Engineering 2
(Date:7/22/2014)... will hear that drinking milk helps make their bones strong or ... foster the idea that if something is good for us, it ... Journal of Consumer Research , when children hear about the ... "We predicted that when food is presented to children as making ... as learning how to read or count, they would conclude the ...
(Date:7/22/2014)... and Shenzhen, China July 22, 2014 ... subsidiary of BGI, the world,s largest genomics organization, ... human whole exome sequencing service based on Complete ... in-depth bioinformatics analysis and SNP validation, and is ... , Complete Genomics, highly regarded in the ...
(Date:7/22/2014)... -- Nancy Buccola, MSN, APRN, PMHCNS-BC, CNE, Assistant ... Center New Orleans School of Nursing, contributed samples ... genetic material associated with schizophrenia and also suggesting ... schizophrenia. The study, Biological insights from 108 schizophrenia-associated ... in Nature , available at http://www.nature.com/nature/journal/vaop/ncurrent/full/nature13595.html., ...
Breaking Biology News(10 mins):BGI Tech launches human whole exome sequencing service on complete genomics' advanced platform 2LSUHSC contributes to work identifying new DNA regions associated with schizophrenia 2
... a growing body of evidence that continued smoking after a ... survival, risk of other cancers, and quality of life, up ... so or relapse after trying to quit. , The ... a peer-reviewed journal of the American Cancer Society, says smoking ...
... GI infections in families with children in day careUsing an ... infections in the home, according to a study in the ... Greater Boston families -- half of which were given hand ... percent reduction in the spread of GI illnesses. , ...
... how the inhaled form of anthrax disarms bacteria-fighting white blood ... most victims within days. , The lethal toxin in anthrax ... body's first defense against infection, by impairing how they build ... body and eat invading bacteria. , Just two hours of ...
Cached Biology News:Many smokers fail to quit after cancer diagnosis 2Hand sanitizer gel works 2Anthrax stops body from fighting back, study shows 2Anthrax stops body from fighting back, study shows 3
... is a new product number, ... product number. If showing no ... the old Sigma-Aldrich number (Z71,669-3) ... assistance. ID clarifier: barcoded Mfr ...
Rabbit polyclonal to YANK2 ( Abpromise for all tested applications). Antigen: A KLH conjugated synthetic peptide selected within aa 300~400 (C terminal region) of human YANK2. Entrez Gene ID:...
... Freedom EVO96R and Freedom EVO384R are fast ... available in three different sizes, with a ... They deliver significant time saving, with true ... easy setup of your assays with the ...
Request Info...
Biology Products: